{
  "Country": "EN",
  "PICOs": [
    {
      "Population": "People who have previously had platinum-doublet chemotherapy",
      "Intervention": "Sotorasib (960 mg once a day until disease progression, treatment discontinuation or the end of the study)",
      "Comparator": "Docetaxel monotherapy and docetaxel plus nintedanib",
      "Outcomes": "Objective response rate of 37.1% (95% confidence interval 28.6 to 46.2)"
    },
    {
      "Population": "People with advanced cancer after platinum-based chemotherapy",
      "Intervention": "Sotorasib",
      "Comparator": "Docetaxel",
      "Outcomes": "Clinical effectiveness and cost-effectiveness, with ongoing data collection to resolve uncertainties"
    }
  ]
}